Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response.

Zhou, Q; Gampenrieder, SP; Frantal, S; Rinnerthaler, G; Singer, CF; Egle, D; Pfeiler, G; Bartsch, R; Wette, V; Pichler, A; Petru, E; Dubsky, PC; Bago-Horvath, Z; Fesl, C; Rudas, M; Ståhlberg, A; Graf, R; Weber, S; Dandachi, N; Filipits, M; Gnant, M; Balic, M; Heitzer, E.

Clin Cancer Res. 2021 Dec 3. doi: 10.1158/1078-0432.CCR-21-3231. Online ahead of print.

https://pubmed.ncbi.nlm.nih.gov/34862246/